Naslov
New therapeutic strategies in frequent interstitial lung disease

Autori
Peroš-Golubičić, Tatjana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Zbornik radova Toraks 2012 / - , 2012

Skup
Toraks 2012

Mjesto i datum
Zagreb, Hrvatska, 20.09.2012. - 23.09.2012

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Nije recenziran

Ključne riječi
Interstitial lung disease; therapy

Sažetak
The treatment of patients with sarcoidosis is mandatory in cardiac, eye, neurological or severe pulmonary sarcoidosis, but in most other instances systemic therapy is not necessary. Corticosteroids are the most effective drugs against sarcoidosis and its complications. Hydroxychloroquine (Plaquenil) is useful in chronic skin lesions, hypercalcemia, and neurosarcoidosis. Methotrexate, azathioprine and leflunomide have been used in sarcoidosis that is refractery to corticosteroids, in patients with severe cortocosteroid side effects and steroidophobs. The most effective second choice drug today is methotrexate. Infliximab, thalidomide and pentoxifylline are anti-TNF agents that are found to be effective in some sarcoidosis patients ; the guidelines for infliximab usage have been reported recently. The novel medications for idiopathic pulmonary fibrosis (IPF) are the result of progress in understanding of pathogenesis of this disease. Pirfenidone, and N-acetylcystein are the only drugs that are recommended, although weakly. N-acetylcysteine, an antioxidant, reduces the rate of decline in forced vitalcapacity and diff using capacity for carbon monoxide after 12 months of treatment. Pirfenidone, a novel compound that inhibits TGFβ in vitro, decreases the rate of decline in vital capacity and increases the progression free survival time over 52 weeks. Corticosteroids alone or in a combination with azathioprine have recently been shown to cause increased mortality in IPF patients, so they should be avoided. The studies have been completed on several agents like colchicine, interferon gamma-1, etanercept (anti TNF agent), bosentane (an oral dual endothelin-1 receptor antagonist), blocking agents of connective tissue growth factor (CTGF) and others, but they did not show any effect on IPF.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA